[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Edelstein et al., 2023 - Google Patents

SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study

Edelstein et al., 2023

View PDF
Document ID
14017775428246423629
Author
Edelstein G
Boucau J
Uddin R
Marino C
Liew M
Barry M
Choudhary M
Gilbert R
Reynolds Z
Li Y
Tien D
Sagar S
Vyas T
Kawano Y
Sparks J
Hammond S
Wallace Z
Vyas J
Barczak A
Lemieux J
Li J
Siedner M
Publication year
Publication venue
Annals of Internal Medicine

External Links

Snippet

Background: Data are conflicting regarding an association between treatment of acute COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To compare the frequency of VR in patients with and without NR treatment for acute COVID-19 …
Continue reading at www.acpjournals.org (PDF) (other versions)

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • G06F19/322Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • G06F19/366Acquisition of data related to laboratory tests, e.g. special identifiers for examination containers
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/345Medical expert systems, neural networks or other automated diagnosis
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work
    • G06Q50/24Patient record management
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00Digital computing or data processing equipment or methods, specially adapted for specific functions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00Administration; Management
    • G06Q10/10Office automation, e.g. computer aided management of electronic mail or groupware; Time management, e.g. calendars, reminders, meetings or time accounting

Similar Documents

Publication Publication Date Title
Edelstein et al. SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study
Oliver et al. Group A Streptococcus pharyngitis and pharyngeal carriage: a meta-analysis
Follmann et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial
Mariani et al. CureGN study rationale, design, and methods: establishing a large prospective observational study of glomerular disease
McKay et al. Performance evaluation of serial SARS-CoV-2 rapid antigen testing during a nursing home outbreak
Schrom et al. Comparison of SARS-CoV-2 reverse transcriptase polymerase chain reaction and BinaxNOW rapid antigen tests at a community site during an Omicron surge: a cross-sectional study
Tabone et al. Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis
Gupta et al. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa
Tang et al. Assessment of SARS-CoV-2 seropositivity during the first and second viral waves in 2020 and 2021 among Canadian adults
Nijman et al. C-reactive protein bedside testing in febrile children lowers length of stay at the emergency department
Briggs et al. Seroprevalence of antibodies to SARS-CoV-2 in rural households in Eastern Uganda, 2020-2022
Ochodo et al. Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities
Rogozińska et al. On‐site test to detect syphilis in pregnancy: a systematic review of test accuracy studies
Ochodo et al. Point‐of‐care tests detecting HIV nucleic acids for diagnosis of HIV‐1 or HIV‐2 infection in infants and children aged 18 months or less
Samsunder et al. Clinical evaluation of severe acute respiratory syndrome coronavirus 2 rapid antigen tests during the omicron wave in South Africa
Fu et al. Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder
Schramm et al. Potential value of urine lateral-flow lipoarabinomannan (LAM) test for diagnosing tuberculosis among severely acute malnourished children
Olbrich et al. Rapid and accurate diagnosis of pediatric tuberculosis disease: a diagnostic accuracy study for pediatric tuberculosis
Taher et al. Implementation of serological and molecular tools to inform COVID-19 patient management: protocol for the GENCOV prospective cohort study
Gils et al. Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: A mixed-methods evaluation
Cochrane Infectious Diseases Group et al. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV
Adriaenssens et al. Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Yan et al. Predictors of coronavirus disease 2019 hospitalization after sotrovimab in patients with hematologic malignancy during the BA. 1 Omicron surge
Wertenauer et al. Diagnostic efficacy of rapid antigen testing for SARS-CoV-2: the COVid-19 AntiGen (COVAG) study
Agarwal et al. Performance and variability of QuantiFERON Gold Plus assay associated with phlebotomy type